Home Health Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect'
Health

Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect'

Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect'
Key Points

Jun 24th, 2026 Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect' Jamey Millar, Novo Nordisk's Executive Vice President of US Operations, discussed the company's preparations for the upcoming CMS bridge program, which will impact Medicare beneficiaries' access to obesity treatments. Millar highlighted uncertainty about whether patient volume will surge immediately or gradually after the program's July 1 rollout, noting ongoing efforts to educate healthcare providers and pharmacists on...

Jun 24th, 2026 Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect' Jamey Millar, Novo Nordisk's Executive Vice President of US Operations, discussed the company's preparations for the upcoming CMS bridge program, which will impact Medicare beneficiaries' access to obesity treatments. Millar highlighted uncertainty about whether patient volume will surge immediately or gradually after the program's July 1 rollout, noting ongoing efforts to educate healthcare providers and pharmacists on patient eligibility. He speaks with Romaine Bostick & Katie Greifeld on "The Close." [Image text:] NOVO NORDISK 47.46 -3.43 6.73% NVO Year toDate 66.00 50.00 Jan Feb Mar 34.00 Apr May 2026 Jun Bloomberg TheClose NOVOWEGOVYPILLSALES SEEN21%ABOVE CONSENSUS:BI
Novo Nordisk US EVP (ORG) Wegovy (ORG) Novo Nordisk (ORG) Jamey Millar (PERSON) Novo Nordisk's (ORG) US Operations (ORG) CMS (ORG) Medicare (ORG) Millar (PERSON) Romaine Bostick & Katie Greifeld (ORG)
Originally published by Bloomberg Markets Read original →